Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatment with rio...

Cur síos iomlán

Sábháilte in:
Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Alberto M. Marra, Michael Halank, Nicola Benjamin, Eduardo Bossone, Antonio Cittadini, Christina A. Eichstaedt, Benjamin Egenlauf, Satenik Harutyunova, Christine Fischer, Henning Gall, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Tobias Lange, Karen M. Olsson, Hans Klose, Ekkehard Grünig
Formáid: Artigo
Teanga:Béarla
Foilsithe / Cruthaithe: 2018
Rochtain ar líne:https://doi.org/10.1186/s12931-018-0957-y
https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-018-0957-y
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!